This Euromonitor market report provides market trend and market growth analysis of the Consumer Health industry in United Kingdom. With this market report, you' ll be able to explore in detail the changing shape and potential of the industry. You will now be able to plan and build strategy on real industry data and projections.

The Consumer Health in United Kingdom market research report includes:

Analysis of key supply-side and demand trends
Detailed segmentation of international and local products
Historic volumes and values, company and brand market shares
Five year forecasts of market trends and market growth
Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

What is the market size of Consumer Health in United Kingdom?
What are the major brands in United Kingdom?
What are the main trends in OTC Healthcare?

Why buy this report?

Gain competitive intelligence about market leaders
Track key industry trends, opportunities and threats
Inform your marketing, brand, strategy and market development, sales and supply functions

EXECUTIVE SUMMARY

Budget cuts to impact National Health Service

Uncertain economic conditions and the formation of the new government have resulted in the announcement of many cost-cutting measures. The NHS in the UK is also expected to see budget cuts starting at the end of 2011. If the government' s plans are approved by the parliament, the NHS will be restructured, giving more freedom to GPs in running their practises. The NHS is expected to make a cost-saving of £20 billion by 2014 through restructuring and redundancies. Such a scenario provides opportunities for players in the industry to drive POM to P and GSL switches. The past year has seen some important POM to P switches in the OTC category. Since the NHS is concerned regarding time spent on treating minor ailments, it is highly likely that the MHRA will also drive such switches, within reason.

Consolidation in the industry continues

Key players in the industry were involved in major acquisitions in 2010. Although economic conditions were uncertain, this gives reason to hope that the future will offer better prospects for the industry. Reckitt Benckiser Plc acquired SSL International Plc, while GlaxoSmithKline Plc acquired Maxinutrition Ltd. To future-proof their revenue growth and ensure sustained growth in the overall category, companies are resorting to inorganic growth through acquisition. Such acquisitions are also result of the fact that the kind of investment required to start from scratch in the pharmaceutical industry is higher, and it makes strategic sense to grow through acquisition in some categories

Changing lifestyle choices provide growth opportunity in sports nutrition

Obesity concerns in the UK have paved way for double-digit growth for the sports nutrition category. The sports nutrition category consists of products used to improve physical endurance especially for gym-goers. This category has grown from a low base and had witnessed significant growth over the last few years. Players involved in this niche have also enjoyed positive growth. The leader in sports nutrition was also an acquisition target towards the end of 2010. With the acquisition completed, this category will continue to experience higher growth prospects, driven by the parent company, a leading pharmaceutical multinational.

Innovative new products lead to value growth

Companies continue to provide new products to consumers targeting innovation and ease of use. Reckitt Benckiser Plc led with such launches. Two of the company' s new product launches - Bonjela Complete Plus for the treatment of mouth ulcers, and Scholl Fungal Nail Treatment, were examples of such launches. While the former provided a gel formula to form a plaster over mouth ulcers and heal them, the latter was positioned as an “all-in-one” product to treat nail fungal infections. The need for portable packaging and all-in-one solutions has led to innovation and stifled demand for traditional product types. Such products can also help fend off competition from private label and generics is an increasingly competitive market

Supermarkets steals shares from specialists

Consumers in Britain are becoming more comfortable with self-medicating and buying OTC medicines through supermarkets. Supermarkets are stealing share from specialists, as they offer greater convenience, promotions and the availability of private label products targeting the lower end of the market. The upsurge in demand for private label products has fuelled price competition in categories such as analgesics, cough and cold remedies, hay fever remedies and medicated confectionery, where the presence of supermarket labels is more prevalent, and undercut branded products quite severely in terms of price. Boots UK Ltd. also launched the Boots Pharmaceutical range in 2010, positioning its products as direct competition to brands from major pharmaceuticals companies.

METHODOLOGY

Global insight and local knowledge

With 40 years' experience of developed and emerging markets, Euromonitor International' s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market' s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Consumer Health in the United Kingdom - Industry Overview

EXECUTIVE SUMMARY

Budget cuts to impact National Health Service
Consolidation in the industry continues
Changing lifestyle choices provide growth opportunity in sports nutrition
Innovative new products lead to value growth
Supermarkets steals shares from specialists
KEY TRENDS AND DEVELOPMENTS
Government budget cuts will result in more drug switches from POM to P, GSL
Major players looking to grow through acquisition
Consumer lifestyle changes provide strong opportunities for growth
Hale and hearty times for private label
Value growth through innovation

MARKET INDICATORS

Table 1. Consumer Expenditure on Health Goods and Medical Services 2005-2010
Table 2. Life Expectancy at Birth 2005-2010

MARKET DATA

Table 3. Sales of Consumer Health by Category: Value 2005-2010
Table 4. Sales of Consumer Health by Category: % Value Growth 2005-2010
Table 5. Consumer Health Company Shares by Value 2006-2010
Table 6. Consumer Health Brand Shares by Value 2007-2010
Table 7. Penetration of Private Label by Category 2005-2010
Table 8. Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
Table 9. Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
Table 10. Forecast Sales of Consumer Health by Category: Value 2010-2015
Table 11. Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC Registration and Classification

SWITCHES

Summary 1. OTC Healthcare Switches 2007-2010
Self-medication/self-care and preventative medicine

DEFINITIONS

Summary 2. Research Sources

Consumer Health in the United Kingdom - Company Profiles

Boots UK Ltd. in Consumer Health (United Kingdom)

STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
- Summary 5. Boots UK Ltd.: Competitive Position 2010
GlaxoSmithKline Plc in Consumer Health (United Kingdom)
STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
COMPETITIVE POSITIONING
- Summary 7. GlaxoSmithKline Plc: Competitive Position 2010

Healthspan Ltd. in Consumer Health (United Kingdom)

STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
- Summary 9. Healthspan Group Ltd.: Competitive Position 2010

Holland & Barrett Retail Ltd. in Consumer Health (United Kingdom)

STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
- Summary 12. Holland & Barrett Retail Ltd.: Competitive Position 2010

Lane Health Products Ltd., GR in Consumer Health (United Kingdom)

STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
COMPETITIVE POSITIONING
- Summary 14. GR Lane Health Products: Competitive Position 2010

McNeil Healthcare (UK) Ltd. in Consumer Health (United Kingdom)

STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
COMPETITIVE POSITIONING
- Summary 16. McNeil Consumer Healthcare UK Ltd.: Competitive Position 2010

Mentholatum Co., Ltd., The in Consumer Health (United Kingdom)

STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
- Summary 18. Mentholatum Co., Ltd., The: Competitive Position 2010

Pfizer Consumer Healthcare Ltd. in Consumer Health (United Kingdom)

STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
- Summary 20. Pfizer Consumer Healthcare: Competitive Position 2010

Reckitt Benckiser Plc in Consumer Health (United Kingdom)

STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
- Summary 23. Reckitt Benckiser: Competitive Position 2010
Vitabiotics Ltd. in Consumer Health (United Kingdom)
STRATEGIC DIRECTION
KEY FACTS
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
- Summary 26. Vitabiotics Ltd.: Competitive Position 2010

Adult Mouth Care in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 adult mouth care achieved sales worth £32 million, down 2% in current value terms on 2009. Although a decline in sales value, the rate of decline was less severe than in 2009. This may be in part attributable to heavy advertising by GlaxoSmithKline, which is generally considered to have helped to raise awareness regarding oral care. However, more widespread health consciousness, changing eating habits, a growing ageing population combined with a desire to stay younger for longer have impacted consumer attitudes to mouth care, and represented key factors fuelling demand. Dentists are also changing their emphasis in terms of patient education, turning their focus more towards gum disease rather than tooth decay.
SWITCHES
COMPETITIVE LANDSCAPE
- Reckitt Benckiser' s Bonjela has a strong presence in adult mouth care, leading with a value share of over 30%. To further improve penetration the company continued to innovate, and in March 2010 launched Bonjela Complete Plus. The gel creates a protective barrier that covers and sticks like a plaster, protecting ulcers for up to four hours, according to the manufacturer. The use of the plaster and soft precession applicator has been introduced for more accurate and hygienic application reducing the chance of cross-contamination.
PROSPECTS
- The adult mouth care environment is expected to decline by a 1% CAGR over the forecast period. One of the major challenges for companies operating in adult mouth care is that only 50% people suffering mouth ulcers actually treat them, as revealed through interviews with major players. Raising awareness and educating consumers is paramount to increasing interest in adult mouth care products, and stimulating future value growth.
CATEGORY DATA
- Table 12. Sales of Adult Mouth Care: Value 2005-2010
- Table 13. Sales of Adult Mouth Care: % Value Growth 2005-2010
- Table 14. Adult Mouth Care Company Shares by Value 2006-2010
- Table 15. Adult Mouth Care Brand Shares by Value 2007-2010
- Table 16. Forecast Sales of Adult Mouth Care: Value 2010-2015
- Table 17. Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- Retail value sales of analgesics in the UK grew 1% in 2010 to reach £533 million. This growth was higher than the increase of just under 1% seen in 2009. Consumers were looking for fast pain relief and continued to trade up to combination analgesics, which resulted in some value increase. Among adult analgesics, combination analgesics and ibuprofen each experienced value growth of 2%. Diclofenac and Naproxen experienced double-digit growth, albeit from a low base.
SWITCHES
COMPETITIVE LANDSCAPE
- Reckitt Benckiser Plc, GlaxoSmithKline Plc and Pfizer Consumer Healthcare Ltd. together accounted for 46% of retail sales in the overall analgesics category at the end of the review period.
PROSPECTS
- Over the forecast period analgesics are expected to show positive value growth with a constant value CAGR of 1% to reach £548 million by 2015. The prominence of private label products will continue to lead to price competition, discounts and drive down overall value. Private label players have also become better placed to offer sophisticated products such as systemic analgesics for lower prices than branded offerings. However, new product developments and the forecast double-digit growth for diclofenac and naproxen will continue to keep value sales buoyant.
CATEGORY DATA
- Table 18. Sales of Analgesics by Category: Value 2005-2010
- Table 19. Sales of Analgesics by Category: % Value Growth 2005-2010
- Table 20. Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
- Table 21. Analgesics Company Shares by Value 2006-2010
- Table 22. Analgesics Brand Shares by Value 2007-2010
- Table 23. Forecast Sales of Analgesics by Category: Value 2010-2015
- Table 24. Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 calming and sleeping products increased by 4% to reach a value of £42 million. This category was driven mainly by the introduction of herbal remedies, as consumers remain cautious regarding the use of sleeping aids but consider more natural remedies acceptable.
SWITCHES
COMPETITIVE LANDSCAPE
- In 2010 Lane Health Products Ltd. led the calming and sleeping products environment, holding a value share of 41%. The company has further extended its Kalms range, introducing lozenges aimed at consumers with increasingly busy schedules. Kalms lozenges contain extract of lemon balm, a Mediterranean herb traditionally used to provide a calming effect on the central nervous system. The product is presented in yellow packaging to stand out on the shelf, and comes in a convenient blister pack.
PROSPECTS
- Sales of calming and sleeping products are expected to see a 1% constant value CAGR over the forecast period as consumers continue to experience disturbed sleep as a result of increasingly fast-paced and demanding lifestyles.
CATEGORY DATA
- Table 25. Sales of Calming and Sleeping: Value 2005-2010
- Table 26. Sales of Calming and Sleeping: % Value Growth 2005-2010
- Table 27. Calming and Sleeping Company Shares by Value 2006-2010
- Table 28. Calming and Sleeping Brand Shares by Value 2007-2010
- Table 29. Forecast Sales of Calming and Sleeping: Value 2010-2015
- Table 30. Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 the cough cold and allergies environment grew by more than 2% in current value terms to reach a value of £637 million. The incidence of cold and flu in 2009/2010 appeared to be lower than in previous years, and the anticipated winter increases in the number of swine flu cases failed to materialise to any great degree.
SWITCHES
COMPETITIVE LANDSCAPE
- In 2010 Reckitt Benckiser led with a 20% share. In November 2010 the company made a £20 million marketing investment into its key cold and germ protection brands, including Dettol, Nurofen, Strepsils and Lemsip. The campaign includes full TV, radio and online support, making it one of the company' s largest seasonal support campaigns. In 2010 Reckitt Benckiser also launched Strepsils Handy Tubes, mainly aimed at the independent category and the on-the-go consumer.
PROSPECTS
- The cough, cold and allergy products environment is expected to remain stagnant in constant value terms over the forecast period. While, sales of cold and flu products increase or decrease markedly depending on the severity of the winter, and can therefore be difficult to predict, many climate scientists agree that human pollution from burning fossil fuels has increased global warming, and overall weather conditions in the UK are expected to be warmer in coming years.
CATEGORY DATA
- Table 31. Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
- Table 32. Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
- Table 33. Sales of Decongestants by Category: Value 2005-2010
- Table 34. Sales of Decongestants by Category: % Value Growth 2005-2010
- Table 35. Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
- Table 36. Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
- Table 37. Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
- Table 38. Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
- Table 39. Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
- Table 40. Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 the digestive remedies category in the UK declined marginally to reach retail value sales of £291 million. The home-cooking trend and the general move towards healthier lifestyles has improved eating habits in the country. People are becoming more health conscious, resulting in a slight decline in demand for digestive remedies. Furthermore, consumers are keen to spend less and are thus happy to trade down to lower cost private label products.
SWITCHES
COMPETITIVE LANDSCAPE
- Reckitt Benckiser Plc led digestive remedies in 2010 with a 28% value share. The company' s strong presence in the indigestion and heartburn remedies and laxatives niches, with its Gaviscon and Senokot brands respectively, is responsible for its leading position. The company has, however, been penalised in the UK for unfair trading practices, being fined £10.2 million by the Office of Fair Trading (OFT). The company was fined because it withdrew original Gaviscon from the NHS in 2005 after its patent expired, and introduced Gaviscon Advance to the NHS, rather than introducing a generic label, thereby restricting competition and abusing its leading position.
PROSPECTS
- Over the forecast period, the digestive remedies environment is expected to decline by a 2% constant value CAGR to reach £262 million in 2015. Most of the digestive remedies environment is mature, and improving consumer lifestyles and eating habits will continue to impact sales of such products.
CATEGORY DATA
- Table 41. Sales of Digestive Remedies by Category: Value 2005-2010
- Table 42. Sales of Digestive Remedies by Category: % Value Growth 2005-2010
- Table 43. Digestive Remedies Company Shares by Value 2006-2010
- Table 44. Digestive Remedies Brand Shares by Value 2007-2010
- Table 45. Forecast Sales of Digestive Remedies by Category: Value 2010-2015
- Table 46. Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- The ear care category reached £10 million in 2010, showing strong growth of 8% that year. This growth was underpinned by new product launches, such as Cerumol Olive Oil Drops. With ear infections being common and affecting people of all ages, demand will likely remain strong. Cerumol is one of the few natural products available in ear care, and as more consumers seek natural products, the launch of more natural-based offerings will be key to driving value growth.
SWITCHES
COMPETITIVE LANDSCAPE
- In 2010 The DDD Group led ear care, holding a value share of 33%. The company' s introduction of Otex Express Combi pack is expected to further bolster sales for DDD in the near future.
PROSPECTS
- Over 2010-2015, the ear care market experienced a growth of 2% CAGR in constant value terms.
CATEGORY DATA
- Table 47. Sales of Ear Care: Value 2005-2010
- Table 48. Sales of Ear Care: % Value Growth 2005-2010
- Table 49. Ear Care Company Shares by Value 2006-2010
- Table 50. Ear Care Brand Shares by Value 2007-2010
- Table 51. Forecast Sales of Ear Care: Value 2010-2015
- Table 52. Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 the emergency contraception category increased by 8% to reach a total sales value of £22 million. Sales were mainly attributable to the Levonelle brand from Schering Healthcare Ltd., which was the only brand available on the OTC market until October 2010.
COMPETITIVE LANDSCAPE
- In 2010 Schering Healthcare Ltd. was the dominant company with a 99.9% share, and as such has focussed advertising and sales growth on building awareness of the product' s availability on an OTC basis.
PROSPECTS
- Sales are expected to continue to grow over the forecast period, despite government TV advertising campaigns warning of the danger of sexually transmitted infections. Sales of emergency contraception products are predicted to see a 4% constant value CAGR over the forecast period.
CATEGORY DATA
- Table 53. Sales of Emergency Contraception: Value 2005-2010
- Table 54. Sales of Emergency Contraception: % Value Growth 2005-2010
- Table 55. Emergency Contraception Company Shares by Value 2006-2010
- Table 56. Emergency Contraception Brand Shares by Value 2007-2010
- Table 57. Forecast Sales of Emergency Contraception: Value 2010-2015
- Table 58. Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 eye care sales in the UK were worth more than £55 million, up 9% on 2009. Introducing more sophisticated segmentation, such as products for dry eyes, tired eyes, redness and irritation was key in driving value growth.
SWITCHES
COMPETITIVE LANDSCAPE
- In 2010, Reckitt Benckiser Plc led the eye care market and was responsible for generating 51% of all value shares.
PROSPECTS
- Over 2010-2015 the eye care category is expected to see a 2% constant value CAGR. Allergy eye care is expected to outperform standard eye care over the forecast period as more allergy-related problems drive consumers towards allergy eye-related products.
CATEGORY DATA
- Table 59. Sales of Eye Care by Category: Value 2005-2010
- Table 60. Sales of Eye Care by Category: % Value Growth 2005-2010
- Table 61. Standard Eye Care by Type: % Value Breakdown 2007-2010
- Table 62. Eye Care Company Shares by Value 2006-2010
- Table 63. Eye Care Brand Shares by Value 2007-2010
- Table 64. Forecast Sales of Eye Care by Category: Value 2010-2015
- Table 65. Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- Interest in herbal/traditional products has grown as emphasis on health and wellness and natural products has increased. Herbal products retail at higher unit prices compared with standard products. Conflicting reports regarding the effectiveness of certain products within the herbal market is, however, still hindering the reputation of herbal products among some consumers.
COMPETITIVE LANDSCAPE
- In 2010 Mars Inc led within herbal/traditional products, responsible 11% of sales value. The majority of sales are achieved through its Tunes and Lockets powerbrands, which held value shares of 6% and 5% respectively in 2010.
PROSPECTS
- The health and wellness trend, coupled with the desire for healthier living, is expected to drive growth over the forecast period. The economic downturn is expected to undermine growth in the short term, but growth is expected to be more dynamic over the forecast period. Increasing consumer awareness of functional food and drinks may encourage consumers to seek alternatives to conventional OTC healthcare products. The side effects of conventional medicines may also turn consumers towards herbal/traditional alternatives, as these are viewed as much safer.
CATEGORY DATA
- Table 66. Sales of Herbal/Traditional Products: Value 2005-2010
- Table 67. Sales of Herbal/Traditional Products: % Value Growth 2005-2010
- Table 68. Herbal/Traditional Products Company Shares 2006-2010
- Table 69. Herbal/Traditional Products Brand Shares 2007-2010
- Table 70. Forecast Sales of Herbal/Traditional Products: Value 2010-2015
- Table 71. Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 the medicated skin care environment was worth £427 million, up only marginally in current terms on the previous year.
SWITCHES
COMPETITIVE LANDSCAPE
- In 2010 Reckitt Benckiser held the leading position in medicated skin care with 12% of value sales. Bayer held second position with a notable presence in antifungals and antiseptics, with leading brands Canesten and Duofilm and Germolene respectively. To raise awareness and sales for this category Bayer launched an online resource on fungal infections aimed at pharmacists and other health professionals. The website was designed to enhance knowledge that in turn gives more educated advice to the consumer. Furthermore, in January 2011 the company launched a £1.5 million national television advertising campaign for thrush brand Canesten. The company expects this to boost sales by over 30%, with the campaign broadcast from 10 January to 27 March 2011.
PROSPECTS
- Sales of medicated skin care products are expected to see a slightly negative constant value CAGR over the forecast period to stand at £408 million in 2015.
CATEGORY DATA
- Table 72. Sales of Medicated Skin Care by Category: Value 2005-2010
- Table 73. Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
- Table 74. Acne Treatments by Format: % Value Breakdown 2005-2010
- Table 75. Medicated Skin Care Company Shares by Value 2006-2010
- Table 76. Medicated Skin Care Brand Shares by Value 2007-2010
- Table 77. Acne Treatments Brand Shares by Value 2007-2010
- Table 78. Hair Loss Treatments Brand Shares by Value 2007-2010
- Table 79. Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
- Table 80. Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- Retail sales of NRT smoking cessation aids in the UK grew by 3% in current value terms in 2010 to reach £111 million. The government' s spending cuts have had an indirect positive influence on the NRT smoking cessation category. In a bid to reduce NHS spending on treating people suffering from the effects of long-term smoking and passive smoking, the government has engaged in more in-depth integration with the NHS Stop Smoking service. According to statistics released by the NHS Stop Smoking Service: England, over April 2009 to March 2010 7,57,537 people set a quit date through the NHS Stop Smoking Service. This represented a 13% increase from the number in 2008/9. Furthermore, 49% of those who set a quit date gave up smoking following a 4-week follow-up. 65% of all those who set a quit date received nicotine replacement therapy. The report also indicates that the total cost of running the NHS Stop Smoking Services was around £84 million over 2009/2010, and increased by 14% from the previous year' s expenditure.
SWITCHES
COMPETITIVE LANDSCAPE
- In 2010 McNeil Healthcare (UK) Ltd. was the leader in NRT smoking cessation aids with a 37% value share for its Nicorette brand. GlaxoSmithKline Plc' s brand Niquitin ranked second with 28%, while Nicotinell from Novartis Consumer Health UK Ltd. was third with 22%. Nicorette was the leader throughout the review period. However, its value share decreased from 39% in 2005 to 37% in 2010. This is mainly attributed to more robust new product developments by the other two players, and greater general awareness of NRT smoking cessation aids among consumers.
PROSPECTS
- Over the forecast period sales of NRT smoking cessation aids are expected to see a 2% CAGR in constant value terms. The government initiatives and cost-cutting agenda will continue to have a positive influence on this category over the forecast period.
CATEGORY INDICATORS
- Table 81. Number of Smokers by Gender 2005-2010
CATEGORY DATA
- Table 82. Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
- Table 83. Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
- Table 84. NRT Gum Flavours: % Value Breakdown 2006-2010
- Table 85. NRT Smoking Cessation Aids Company Shares by Value 2006-2010
- Table 86. NRT Smoking Cessation Aids Brand Shares by Value 2007-2010
- Table 87. Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
- Table 88. Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

OTC Triptans in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 sales of OTC triptans were worth approaching £5 million, up 35% in current terms on 2009. Migraines already affect 15% of adults in the UK, equivalent to almost six million people, and with people' s lives becoming increasingly stressful, susceptibility to migraines is increasing.
COMPETITIVE LANDSCAPE
- In 2010, GlaxoSmithKline held 100% sales, being the only company with such a product available as OTC medicine.
PROSPECTS
- Over 2010-2015 the OTC triptans environment is expected to see a 9% constant value CAGR. Growth is expected to be on the back of an increase in the number of migraine incidences as consumer lifestyles continue to become more hectic and stressful.
CATEGORY DATA
- Table 89. Sales of OTC Triptans: Value 2006-2010
- Table 90. Sales of OTC Triptans: % Value Growth 2006-2010
- Table 91. OTC Triptans Company Shares by Value 2006-2010
- Table 92. OTC Triptans Brand Shares by Value 2007-2010
- Table 93. Forecast Sales of OTC Triptans: Value 2010-2015
- Table 94. Forecast Sales of OTC Triptans: % Value Growth 2010-2015

Sports Nutrition in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- Retail value sales of sports nutrition products grew by 14% in 2010 to reach £200 million. Continued interest from enthusiastic/active consumers kept sales quite strong. Historically the category experienced stronger growth in retail value sales because of lower penetration rates. The current value CAGR over 2005-2010 was 21%. At the time of writing growth has partially stabilised but remains strong due to marketing efforts implemented by the companies involved.
COMPETITIVE LANDSCAPE
- In 2010 Maxinutrition Ltd. led within sports nutrition with 35% of value sales, followed by Holland & Barrett Retail Ltd. with its own brand - Body Fortress - on 15%. Due to the phenomenal growth in the category, most players saw double-digit growth in value sales at the end of the review period.
PROSPECTS
- Over the forecast period sports nutrition is expected to see a 9% constant value CAGR to reach £312 million by 2015. British consumers will continue to pay attention to their health, and the increasing number of people engaging in sporting activities and deciding to lead a healthy lifestyle will help the growth of this category. The increased sales of sports nutrition products through supermarkets is expected to lead to price discounts and reduce the value of the market over the forecast period to some extent.
CATEGORY DATA
- Summary 27 Sports Nutrition Category Rankings 2010
- Table 95. Sales of Sports Nutrition: Value 2005-2010
- Table 96. Sales of Sports Nutrition: % Value Growth 2005-2010
- Table 97. Sports Nutrition By Format: % Value Breakdown 2007-2010
- Table 98. Sports Nutrition Company Shares 2006-2010
- Table 99. Sports Nutrition Brand Shares 2007-2010
- Table 100. Forecast Sales of Sports Nutrition: Value 2010-2015
- Table 101. Forecast Sales of Sports Nutrition: % Value Growth 2010-2015

Vitamins and Dietary Supplements in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- Health conscious consumers of the UK continued to sustain growth in this category at the end of the review period. Recession-related stress has also led to consumers assessing their priorities in life, hence value growth over 2009/2010 was almost comparable with that of 2008/2009. The major impact of the credit crunch was that consumers became conscious of spending, and want to know that they are buying the best for themselves and their family. Consumers who buy vitamins and dietary supplements during their weekly trips to the supermarket have reassessed their shopping habits, and are making informed decisions on the supplements they need rather than everything that is available.
VITAMINS
DIETARY SUPPLEMENTS
COMPETITIVE LANDSCAPE
- Within vitamins and dietary supplements, the competitive landscape remains largely unchanged in terms of the leading companies, and continues to be highly fragmented. Holland & Barrett Retail Ltd. ranked number one within this category with a 13% value share in 2010. Seven Seas Ltd. and Vitabiotics Ltd. ranked second and third respectively with value shares of 10% and 9%.
PROSPECTS
- Over the forecast period the vitamins and dietary supplements environment is expected to see a constant value CAGR of 1% to reach £771 million in 2015. Growth will come from health conscious consumers as well as the ageing population in the UK.
CATEGORY DATA
- Summary 28 Dietary Supplements: Brand Ranking by Positioning 2010
- Table 102. Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
- Table 103. Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
- Table 104. Dietary Supplements by Positioning 2005-2010
- Table 105. Vitamins and Dietary Supplements Company Shares by Value 2006-2010
- Table 106. Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
- Table 107. Vitamins Brand Shares by Value 2007-2010
- Table 108. Dietary Supplements Brand Shares by Value 2007-2010
- Table 109. Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
- Table 110. Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015

Weight Management in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- Retail sales of weight management products in the UK grew by 13% in current value terms in 2010 to reach £143 million. OTC obesity pills Alli grew by 45% to reach £39 million. This not only provided double-digit growth for the overall category, but also revived interest in other weight loss supplements. The category' s growth prior to the launch of Alli in 2009 was only 2% in retail value terms. Hence, it is evident that the high growth of the category was derived from the launch of Alli.
COMPETITIVE LANDSCAPE
- In 2010 GlaxoSmithKline Plc ranked number one in weight management with a 27% value share in retail sales, while Unilever Foods UK Ltd. was second with 21% and Herbalife (UK) Ltd. third with 11%.
PROSPECTS
- Over the forecast period the weight management category is expected to grow by a 6% constant value CAGR to reach £192 million in 2015. Obesity in the UK remains a serious concern for the nation as a whole. Government efforts to bring the UK back on track in terms of obesity, growing consumer awareness of healthy lifestyles and consumers' interest in changing their lifestyles as a whole rather than seeking quick fixes will all aid growth in this category. OTC obesity drug Alli is expected to gain share, especially targeting consumers with a BMI of 28 kg/m2 and over.
CATEGORY DATA
- Table 111. Sales of Weight Management: Value 2005-2010
- Table 112. Sales of Weight Management: % Value Growth 2005-2010
- Table 113. Weight Management Company Shares 2006-2010
- Table 114. Weight Management Brand Shares 2007-2010
- Table 115. Forecast Sales of Weight Management: Value 2010-2015
- Table 116. Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in the United Kingdom - Category Analysis

HEADLINES
TRENDS
- In 2010 wound treatments declined 5% in current value terms to a value of £59 million. The industry has responded to strong private label competition in the past few years with the introduction of new technologies, such as silver-infused plasters, aimed at accelerating wound healing, and catering more to niche consumer segments with sensitive skin types, such as diabetics. Spray plasters were introduced to the UK market in 2003. These products contain alginates or oxidised cellulose and act by clotting blood at the surface of the skin, making them ideal for superficial wounds and grazes. Elastoplast went a step further with the introduction of silver: a nano-crystalline technology with antibacterial properties. The introduction of private label plasters, such as Boots' Advanced First Aid plaster, is expected to hamper value sales growth for the category, however.
COMPETITIVE LANDSCAPE
- Beiersdorf UK Ltd. led wound care in 2010 with a 33% value share. The company has innovated with the introduction of spray-on plasters, and was the first to introduce faster healing plasters. However, the competition from private label products is undercutting value sales for the company. The company introduced three new plasters, plasters with healing cream 2-in-1 and cold sore patches.
PROSPECTS
- Over the forecast period wound care is expected to see a -4% constant value CAGR. The increasingly price competitive presence of private label products is expected to undercut value growth for the wound care industry, despite on-going product innovation.
CATEGORY DATA
- Table 117. Sales of Wound Care by Category: Value 2005-2010
- Table 118. Sales of Wound Care by Category: % Value Growth 2005-2010
- Table 119. Wound Care Company Shares by Value 2006-2010
- Table 120. Wound Care Brand Shares by Value 2007-2010
- Table 121. Forecast Sales of Wound Care by Category: Value 2010-2015
- Table 122. Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

英國的消費者保健市場

Consumer Health in the United Kingdom

簡介